DOI: http://dx.doi.org/10.18203/2349-2902.isj20210065

A study of serum levels of prostate specific antigen, prostate acid phosphatase in prostate cancer patients and its complications on liver

Balakrishna S. V., Veerabhadra Goud G. K., Veluri Ganesh

Abstract


Background: The prostate cancer (PC) is most leading disorders in human beings particularly in males. Prostate specific antigen (PSA) and prostate acid phosphatase (PAP) are tumor markers useful for early detection and diagnosis of PC. In prostate cancer patients more prone to liver and bone cancer metastasis because in these patients elevated levels of serum liver function tests (LFT) and these liver enzymes more specific for early detection of pathological changes in liver and bones.

Methods: This is the case control study was carried out the association of serum levels of PSA/PAP inpatients with prostate cancer and healthy controls. Total 120 subjects included in this study in that 60 PC patients and 60 controls was included and blood was collected. The serum PSA levels are estimated by ELISA, PAP estimated by Kinetic method and LFT Was analyzed by commercial kits. 

Results: The present study evaluates the serum levels of LFT, PSA and PAP in patients with prostate cancer and compared with the healthy controls. The statistically significant difference between the PSA, PAP and LFT levels in patients with PC when compared to controls. The positive correlation in between PSA, PAP with LFT (p=0.001).

Conclusions: This study suggesting that the serum PSA, PAP levels sensitive parameters for early detection of prostatic cancer and also for these patients’ frequent measurements of serum liver function tests, useful for early detection of significant pathological changes occurs in the liver and bone cancers metastasis from prostate.   


Keywords


Prostate specifics antigen, Prostatic acid phosphatase, Liver function tests, Prostate cancer

Full Text:

PDF

References


Christudoss P, Selvakumar R, Fleming JJ, Gopalakrishnan G. Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma. Indian J Urol. 2011:27(1);14-8.

Shahana S, Abdul Majid Adil M, Parveen N, Ishaq M. Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. Hindawi Prostate Cancer. 2015:8(12);18-27.

Vickers AJ. Prostate cancer screening: time to question how to optimize the ratio of benefits and harms. Ann Intern Med. 2017;167:509-10.

Lin K, Lipsitz R, Miller T, Janakiraman S. U.S. Preventive Services Task Force Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192-9.

Catalona WJ, Partin AW, Slawin KM. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Asso. 1998:279(19);1542-7.

McNeal JE. Regional morphology and pathology of the prostate. Am J Clin Pathol. 1968:49(3);347-57.

Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987:1(38);1181-4.

Rama Devi M, Mahendra Kumar S, Charles S, Gourdas C. Total PSA and free PSA in patients with severe liver dysfunction. Indian J Urol. 2003:19;117-9.

Banez LL, Loftis RM, Freedland SJ, Presti JC, Aronson WJ, Amling C et al. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy. Prostate Cancer Prostatic Dis. 2010:13;173-7.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007:99;1375-83.

Han PK, Kobrin S, Breen N, Joseph DA, Li J, Frosch DL et al. National evidence on the use of shared decision making in prostate-specific antigen screening. Ann Fam Med. 2013:11;306-14.

Dragan L, Djulbegovic M, Hung Jung J, Hwang EC, Zhou Q, Anne C et.al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018:362;1-12.

US Preventive Services Task Force: Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW et al. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018:319(18);1901-13.

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018:319;1914-31.

Sarwar S, Adil MAM, Nyamath P, Ishaq M. Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus. Prostate Cancer. 2017;5;1-7.

Vihko P, Kontturi M, Korhonen LK. Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin Chem. 1978;24(3):466-70.

Gunia S, Koch S, May M, Dietel M, Erbersdobler A. Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows Archiv. 2009;454(5):573-9.

Mazhar D, J Waxman. Prostate cancer. Postgraduate Med J. 2002;78(924):924-58.

Kirschenbaum A, Izadmehr S, Yao S. Prostatic acid phosphatase alters the RANKL/OPG system and induces osteoblastic prostate cancer bone metastases. Endocrinol. 2016:157(12);4526-33.

Larson SR, Chin J, Zhang X. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Meta. 2014:31(2);247-56.

Johansen JS, Brasso K, Iversen P. Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res. 2007;13:3244-9.

Schröder FH, Bertrand T, Miller K, Boccon-Gibod L, Neal DS, Crawford ED, et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. B J U Int J Compilation. 2009;106:182-7.